Open Access

AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy

  • Authors:
    • Syed Minhaj Uddin Ahmed
    • Zi Nong Jiang
    • Zhao Hong Zheng
    • Yulong Li
    • Xiu Jun Wang
    • Xiuwen Tang
  • View Affiliations

  • Published online on: November 15, 2018     https://doi.org/10.3892/ol.2018.9705
  • Pages: 773-780
  • Copyright: © Ahmed et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Effective methods for predicting tumor response to preoperative chemotherapy are required. Aldo‑ketoreductase family 1 member B10 (AKR1B10) is predominantly expressed in the gastrointestinal tract and serves an important function in cancer development and progression. The present study investigated whether AKR1B10 expression may predict the therapeutic response of locally advanced gastric cancer. A total of 53 patients with gastric cancer underwent neoadjuvant chemotherapy followed by surgery between January 2006 and December 2015. The protein expression level of AKR1B10 was determined in paraffin‑embedded biopsy specimens using immunohistochemistry. Western blotting confirmed that the AKR1B10 protein is primarily localized to the cytoplasm. χ2 and Fisher's exact tests were used to determine the association of AKR1B10 with a number of clinic opathological features. Univariate and multivariate analyses were used to identify the prognostic factors. Survival rates were compared using Kaplan‑Meier curves with a log‑rank test. The positive rate of AKR1B10 protein expression was 58.5%, whereas 41.5% samples exhibited negative expression. The frequency of AKR1B10‑positive gastric cancer samples was increased in patients with lymph node metastasis and decreased in those exhibiting tumor regression. The 5‑years overall survival rate for the AKR1B10‑positive group was significantly poorer than that for the AKR1B10‑negative group. AKR1B10 expression was associated with lymph node metastasis and a poorer prognosis, along with a poor response to neoadjuvant chemotherapy suggesting that AKR1B10 may be a potential predictor for the therapeutic response of locally‑advanced gastric cancer.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 17 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ahmed SM, Jiang ZN, Zheng ZH, Li Y, Wang XJ and Tang X: AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncol Lett 17: 773-780, 2019
APA
Ahmed, S.M., Jiang, Z.N., Zheng, Z.H., Li, Y., Wang, X.J., & Tang, X. (2019). AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncology Letters, 17, 773-780. https://doi.org/10.3892/ol.2018.9705
MLA
Ahmed, S. M., Jiang, Z. N., Zheng, Z. H., Li, Y., Wang, X. J., Tang, X."AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy". Oncology Letters 17.1 (2019): 773-780.
Chicago
Ahmed, S. M., Jiang, Z. N., Zheng, Z. H., Li, Y., Wang, X. J., Tang, X."AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy". Oncology Letters 17, no. 1 (2019): 773-780. https://doi.org/10.3892/ol.2018.9705